-
Goldman Sachs Upgrades Roche Holding (ROG:SW) (RHHBY) to Neutral
-
Genentech reaches drug pricing agreement with U.S. government
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Genentech's giredestrant cuts breast cancer recurrence risk by 30%
-
Deutsche Bank Upgrades Roche Holding (ROG:SW) (RHHBY) to Hold
-
Jefferies Downgrades Roche Holding (ROG:SW) (RHHBY) to Underperform
-
Genentech reports positive Phase III results for uveitic macular edema drug
-
Genentech launches direct-to-patient program for flu drug Xofluza
-
HSBC Upgrades Roche Holding (ROG:SW) (RHHBY) to Buy
-
Baird on Lineage Cell Therapeutics Inc. (LCTX): 'Incrementally positive following partner's R&D Day'
-
Genentech breaks ground on $700 million manufacturing facility in North Carolina
-
Morgan Stanley Downgrades Roche Holding (ROG:SW) (RHHBY) to Underweight
-
Morgan Stanley Downgrades Roche (RHHBY) to Underweight
-
FDA rejects Genentech's Columvi combination for lymphoma treatment
-
Roche's (RHHBY) Genentech presents results from Phase 3 study of Lunsumio
-
Roche (RHHBY) to invest $550 million for manufacturing hub expansion
-
HSBC Downgrades Roche Holding (ROG:SW) (RHHBY) to Hold
-
BNP Paribas Exane Starts Roche Holding (ROG:SW) (RHHBY) at Outperform
-
UBS Upgrades Roche Holding (ROG:SW) (RHHBY) to Buy
-
Bernstein explains why this Big Pharma stock should 'continue to work'
-
FDA Approves Genentech’s Susvimo as Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
-
Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF265 at Deutsche Bank
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
CFRA Starts Roche (RHHBY) at Hold
-
Erste Group Downgrades Roche Holding (ROG:SW) (RHHBY) to Hold
-
BofA Securities Upgrades Roche Holding (ROG:SW) (RHHBY) to Buy
-
Deutsche Bank Downgrades Roche Holding (ROG:SW) (RHHBY) to Sell
-
Roche stock down 5% after disappointing drug trial data update
-
Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF290 at Berenberg
-
Roche to accelerate weight loss drugs development after positive trials - report
-
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
-
Morgan Stanley Reiterates Underweight Rating on Roche Holding (ROG:SW) (RHHBY)
-
Jefferies Reiterates Hold Rating on Roche Holding (ROG:SW) (RHHBY)
-
Deutsche Bank Reiterates Buy Rating on Roche Holding (ROG:SW) (RHHBY)
-
Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF305 at Bernstein SocGen Group

